With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5317-33-9,3-(4-Methylpiperazin-1-yl)propan-1-ol,as a common compound, the synthetic route is as follows.
5317-33-9, To a stirred suspension of the 4-(2-fluoro-4- nitrophenoxy)-6-methoxyquinolin-7-ol (Example 72, step D, 0.15 g, 0.454 mmol) in CH2Cl2 (4 mL) at room temperature under nitrogen was added the 3-(4-methylpiperazin-l-yl)propan-l-ol (0.086 g, 0.545 mmol) followed by PPh3 (0.191 g, 0.727 mmol) and (E)-diethyl diazene-1,2- dicarboxylate (0.127 g, 0.727 mmol). After 17 hours stirring, the reaction was concentrated to a residue under reduced pressure. The crude was purified by silica gel flash column chromatography (10% MeOH in CH2Cl2) to afford 0.185 mg (87%) of the desired product. LRMS (ESI pos) m/e 471 (M+l).
The synthetic route of 5317-33-9 has been constantly updated, and we look forward to future research findings.
Reference：
Patent; ARRAY BIOPHARMA INC.; GENENTECH, INC.; WO2007/146824; (2007); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics